Leslie D Lowe

US Patent:

20030049798, Mar 13, 2003

Filed:

Oct 4, 2001

Appl. No.:

09/972218

Inventors:

Laura Carter - Medford MA, US
Matthew Whitters - Hudson MA, US
Mary Collins - Natick MA, US
Deborah Young - Melrose MA, US
Debra Donaldson - Medford MA, US
Leslie Lowe - Sudbury MA, US
Michelle Unger - Brighton MA, US

International Classification:

C07K014/705
C12P021/04
C12P021/02
C12N005/06

US Classification:

435/069700, 435/320100, 435/325000, 530/350000, 536/023500

Abstract:

Polynucleotides encoding the MU-1 hematopoietin receptor superfamily chain and fragments thereof are disclosed. MU-1 proteins and methods for their production are also disclosed.

US Patent:

20030108549, Jun 12, 2003

Filed:

Oct 4, 2002

Appl. No.:

10/264634

Inventors:

Laura Carter - Medford MA, US
Beatriz Carreno - Acton MA, US
Leslie Lowe - Sudbury MA, US
Matthew Whitters - Hudson MA, US
Mary Collins - Natick MA, US
Margery Ma - Roxbury MA, US
Deborah Young - Melrose MA, US
JoAnn Witek - Acton MA, US
Glenn Larsen - Sudbury MA, US
Marion Kasaian - Charlestown MA, US
Debra Donaldson - Medford MA, US
Michelle Unger - Chapel Hill NC, US

Assignee:

Wyeth - Madison NJ

International Classification:

A61K039/395
A61K031/525
A61K031/4745
A61K031/415

US Classification:

424/145100, 514/251000, 514/291000, 514/406000

Abstract:

Methods and compositions for modulating interleukin-21 (IL-21)/IL-21 receptor (MU-1) activity using agonists or antagonists of IL-21 or IL-21 receptor (“IL-21R” or “MU-1”), are disclosed. IL-21/IL-21R antagonists can be used to induce immune suppression in vivo, e.g., for treating or preventing immune cell-associated pathologies (e.g., pathologies associated with aberrant activity of one or more of mature T cells (mature CD8+, mature CD4+ T cells), mature NK cells, B cells, macrophages and megakaryocytes, including transplant rejection and autoimmune disorders). IL-21/IL-21R agonists can be used by themselves or in combination with an antigen, e.g., as an adjuvant (e.g., a vaccine adjuvant), to up-regulate an immune response in vivo, e.g., for example, for use in treating cancer and infectious disorders.